Evolution of angiogenic and inflammatory biomarkers in patients with hereditary hemorrhagic telangiectasia during treatment with bevacizumab: study protocol
Rev Clin Esp (Barc). 2025 Oct 5:502370. doi: 10.1016/j.rceng.2025.502370. Online ahead of print. ABSTRACT BACKGROUND: Hereditary haemorrhagic telangiectasia (HHT) is a rare disease characterized by mucocutaneous telangiectasia and visceral vascular malformations. Treatment with bevacizumab is recommended in patients with liver involvement and high output heart failure (HOHF) or those with severe gastrointestinal (GI) involvement. However, […]



